For those of you who have been reading this blog for a while, you are familiar with the "Fragments in the Clinic" posts, Jan2015, Jan2013, and Jan2010. Two of those slowly making its way through the pipeline is navitoclax, ABT-263, and venetoclax, ABT-199. Today Abbvie and Genentech announced that it had met its end point in phase II trials. The companies plan to file for approval by the end of this year. At that point we will then have TWO compounds approved from fragments. Congratulations to all of those folks who have worked on this over the years!!!
Subscribe To
Posts
Comments
3 comments:
Great work - but whats its PFI????
I'm surprised venetoclax has a nitro group. I thought nitros were undesirable
in new drugs.
They are undesirable until they are desired.
Post a Comment